Massachusetts General Hospital
This study seeks to better understand the liver's immune response to receiving chemotherapy agent melphalan through Percutaneous Hepatic Perfusion (PHP) alone or in combination with Ipilimumab and Nivolumab for patients with Uveal Melanoma that has metastasized to the liver.
Biopsies and blood samples will be collected before treatment to establish baseline measurements. Patients will then receive either a single dose of Melphalan via Percutaneous Hepatic Perfusion (PHP) or a single dose of Melphalan via Percutaneous Hepatic Perfusion (PHP) in combination with Ipilimumab and Nivolumab per standard of care and return 21-28 days later for a follow-up biopsy and peripheral blood draw. Baseline and post-treatment samples will be compared to evaluate the immune response.
Inclusion Criteria: * Patient has histologically or cytologically confirmed diagnosis of uveal melanoma metastatic to the liver and is determined to be a candidate for percutaneous hepatic perfusion with melphalan * In Cohort B only: patient is determined to be a candidate for percutaneous hepatic perfusion with melphalan combined with Ipilimumab and Nivolumab * The subject has read, signed and dated the Informed Consent Form (ICF), having been advised of the risks and benefits of the trial in a language understood by the subject. * Age \> 18 years at date of informed consent signature having…
Melphalan through Percutaneous Hepatic Perfusion will be received as standard of care.
Melphalan through Percutaneous Hepatic Perfusion in combination with Ipilimumab and Nivolumab will be received as standard of care.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.